Alternative insurance arrangements and the treatment of depression: what are the facts?
Using insurance claims data from nine large self-insured employers offering 26 alternative health benefit plans, we examine empirically how the composition and utilization for the treatment of depression vary under alternative organizational forms of insurance (indemnity, preferred provider organization networks, and mental health carve-outs), and variations in patient cost-sharing (copayments for psychotherapy and for prescription drugs). Although total outpatient mental health and substance abuse expenditures per treated individual do not vary significantly across insurance forms, the depressed outpatient is more likely to receive anti-depressant drug medications is preferred provider organizations and carve-outs than when covered by indemnity insurance. Those individuals facing higher copayments for psychotherapy are more likely to receive anti-depressant drug medications. For those receiving treatment, increases in prescription drug copayments tend to increase the share of anti-depressant drug medication costs accounted for by the newest (and more costly) generation of drugs, the selective serotonin reuptake inhibitors.
Berndt
E R
ER
Harvard Medical School, Boston, MA 02115, USA.
Frank
R G
RG
McGuire
T G
TG
D000928:Antidepressive Agents / Q000627:therapeutic use; D002391:Catchment Area, Health; D017047:Cost Sharing; D017281:Cost of Illness; D003863:Depression / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D007358:Insurance, Psychiatric / Q000191:economics*; D008329:Managed Care Programs / Q000191:economics; D015999:Multivariate Analysis; D015995:Prevalence; D011613:Psychotherapy; D014481:United States / Q000453:epidemiology